Compare Citius Pharmaceuticals Inc (CTXR) vs Snap Inc (SNAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Snap Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M), while Snap Inc trades at $5.51 (market cap $9.05B). The key difference: Snap Inc is far larger — about 483.2× Citius Pharmaceuticals Inc's market cap, and Snap Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | SNAP | |
|---|---|---|
Market Cap | $18.73M | $9.05B |
Sector | Health | Media |
52-Week High | $1.82 | $9.09 |
52-Week Low | $0.48 | $3.93 |
Enterprise Value | $14.95M | $10.61B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
SNAP trades at $5.33, up 2.3% today, with a bullish technical signal and recent Q2 2026 earnings beating expectations. Revenue grew 19% year-over-year to $1.60 billion, and adjusted EBITDA surged 505%. The stock shows improving operational trends but remains unprofitable, with a net income margin of -4.9% for 2025. Analyst consensus price target is $7.02, suggesting potential upside from current levels.
Outlook hinges on sustained advertising recovery and cost discipline. Risks include persistent losses, high debt, and competitive pressure. Institutional sentiment is mixed, with 38% buy ratings but recent insider selling. The stock offers speculative growth potential if profitability improves, but volatility may persist near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Snap Inc
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →
